News/Press

Medical Need announces that the product GranuPAS® has been granted EU marketing authorization by the European Commission on April 7, 2014. The product contains para-aminosalicylic

Medical Need enters into a collaboration with Atlantic Pharmaceuticals on first-in-class therapy for inflammatory bowel disease Medical Need, Stockholm Sweden and Atlantic Pharmaceuticals Ltd, Cambridge

About para-aminosalicylic acid in gastro-resistant granules Para-aminosalicylic acid is used for the treatment of MDR-TB, as part of an appropriate combination regimen, in adults and

Medical Need gains rights to product for the treatment of progressive multiple sclerosis (MS) Medical Need announced today that it has entered into an exclusive

New EU orphan drug designation for the treatment of Congenital Sucrase-Isomaltase Deficiency Medical Need Europe AB earlier announced that the European Commission has approved the

EU Marketing Authorization for the treatment of Urea Cycle Disorders Medical Need announced today that the European Commission on July 31, 2013, issued a marketing

Medical Need and CTD Holdings enter into a partnership for treatment of Niemann-Pick Type C disease Medical Need today announced that it has entered into